International Journal of Trade Economics and Finance

Chen M., Zhang H., Ji P.

Nicotinamide adenine dinucleotide (NAD+) is one of the most essential coenzymes that is widely distributed in human tissues. However, with the progress of aging, the NAD+ level gradually decreases, thus impacting the metabolic dynamics and heightening susceptibility to various pathologies. Increasing NAD+ levels are expected to delay aging and improve age-related degenerative diseases. Amino–carboxylic semialdehyde dehydrogenase (ACMSD) is a key enzyme involved in the de novo synthesis of NAD+. It reduces the intermediate products of the de novo synthesis pathway by catalyzing the degradation of α-amino-β-carboxyethylglutamic acid-ε-semialdehyde (ACMS), thus reducing the production of NAD+. Genetic and pharmacological inhibition of ACMSD has been demonstrated to increase NAD+ levels in vitro and in vivo, thus making it a potential target for the treatment of NAD+-deficient diseases. In this mini-review, we detail the molecular mechanisms regulated by ACMSD. We also discuss the potential efficacy and progress of ACMSD inhibitors in treating aging and age-related diseases.

Jiménez-Romero C., Amador L.A., Castro-Falcón G., Rodríguez A.D.

Background/Objectives: The marine sponge Plakortis halichondrioides is notable for its capacity to accumulate a large array of secondary metabolites. The present research aims at discovering new secondary metabolites from P. halichondrioides with potential applications in medicine. Methods: Plakortilactone (1) and seco-plakortide F acid (2), two new polyketides, along with known manadodioxan D (3), 13-oxo-plakortide F (4), plakortide F (5), and manadodioxan E (6), were isolated from P. halichondrioides. We achieved the structural elucidation of 1 and 2 using modern spectroscopic methods. The relative stereochemistry of 1 was proposed on the basis of 1D- and 2D-NMR data in combination with molecular modeling studies. Additionally, the absolute configuration of 2 was established through chemical correlation to 5. We screened some of the isolated compounds against the malaria parasite Plasmodium falciparum 3D7 non-resistant (wild-type resistant) strain, the tuberculosis bacterium Mycobacterium tuberculosis, the prostate cancer cell line DU-145, and the melanoma cell line A-2058. Results: minimal activity was detected for 2 against these cancer cells. In contrast, 3 and 4 displayed activity against DU-145 cells with IC50 values of 1.6 µg/mL and 4.5 µg/mL, respectively, and A-2058 cells with IC50s of 2.6 µg/mL and 7.7 µg/mL, respectively. In the antiplasmodial activity assay 3 appeared more active (IC50 = 1.7 µg/mL) than 4 (IC50 = 3.1 µg/mL). Meanwhile, 2 displayed only moderate activity (IC50 = 39.3 µg/mL). In the antimycobacterial activity assay 2 exhibited moderate inhibition (MIC = 75.1 µg/mL). In contrast, a 1:1 mixture of 3 and 4 demonstrated higher activity (MIC = 26.3 µg/mL). Conclusions: the biological activity data together with ADMET predictions indicated favorable pharmacokinetic properties for 3.

Tabatabaei S.N., Keykhaee Z., Nooraei S., Ayati M.A., Behzadmand M., Azimi S., Eskati F., Ahmadian G.

COVID-19, first identified in December 2019 in Wuhan, China, is caused by the SARS-CoV-2 virus, a pathogen that primarily targets the respiratory system and can lead to severe conditions such as acute respiratory distress syndrome (ARDS). Among the seven coronaviruses known to infect humans, three—SARS-CoV, MERS-CoV, and SARS-CoV-2—are associated with severe illness and significant morbidity. SARS-CoV-2 is an enveloped, single-stranded RNA virus that utilizes the angiotensin-converting enzyme 2 (ACE2) receptor for cellular entry. The genetic sequence of SARS-CoV-2 is highly mutable, leading to the emergence of variants that alter disease pathology and transmission dynamics. The World Health Organization (WHO) has classified these mutations into variants of concern (VOCs), variants of interest (VOIs), and variants under monitoring (VUMs). This review provides an in-depth analysis of both historical and emerging SARS-CoV-2 variants, summarizes recent advancements in diagnostic methods for SARS-CoV-2 detection, and discusses current therapeutic strategies for COVID-19, with a particular focus on virus-like particle (VLP) vaccines developed in recent years. Additionally, we highlight ongoing therapeutic approaches and their implications for managing COVID-19.

Chaachouay N.

Background/Objectives: The interaction of bioactive compounds derived from plants with drugs has become a significant area of investigation due to its potential to improve, reduce, or have no effect on therapeutic outcomes. Due to the dual effect of these interactions, elucidating the underlying mechanisms is essential for establishing a therapeutic strategy. This study emphasizes the significant findings, mechanisms, and clinical implications of drug–plant bioactive interactions. It calls for more studies to seek safe and effective incorporation into clinical practice. Methods: To identify relevant studies, we performed a systematic literature search based on various scientific databases from 11 August 2024 to 30 December 2024. The search will be based on relevant keywords such as synergy, antagonism, plant bioactive compounds, and drug interactions supplemented with secondary terms such as phytochemicals, herb-drug interactions, pharmacokinetics, and pharmacodynamics. Results: Plant bioactives, including polyphenols, flavonoids, alkaloids, and terpenoids, display valuable biological activities that can interact with medications in three principal ways: synergy, additive effects, and antagonism. Synergy occurs when the combined effects of plant chemicals and pharmaceuticals outweigh the sum of their separate effects, increasing therapeutic effectiveness or allowing dosage decrease to reduce adverse effects. Additive effects occur when the combined impact equals the total individual effects, resulting in better outcomes without increasing risk. Antagonism occurs when a plant ingredient reduces or counteracts the effects of a medicine, thereby jeopardizing treatment. In addition, specific interactions may have no discernible effect. The chemical makeup of bioactive chemicals, medication pharmacokinetics, and individual patient characteristics such as genetics and metabolism all impact the intricacy of these interactions. Conclusions: Pharmacokinetics and pharmacodynamics of drugs can be considerably modulated through their interactions with plant bioactive components, which may cause a significant decrease in efficacy or increase in toxicity of therapeutic agents. More studies are needed to clarify mechanisms of action, prove clinical relevance, and create guidelines for safe co-administration. This integrative approach can mitigate those risks and allow for therapeutic optimization by introducing pharmacogenomics and personalized medicine approaches.

Ebbert L.E., Free T.J., Soltani M., Bundy B.C.

Background/Objectives: Cancer is a leading cause of death. However, recently developed immunotherapies have shown significant promise to improve cancer treatment outcomes and survival rates. Pembrolizumab, a cancer immunotherapy drug, enables a strong T-cell response specifically targeting cancer cells to improve patient outcomes in more than 16 types of cancer. The increasing demand for pembrolizumab, the highest selling drug in 2023, increases global dependence on drug production, which can be vulnerable to supply chain disruptions. Methods: Cell-free protein synthesis (CFPS) is a rapid in vitro protein production method that could provide the production of an immunotherapy drug in an emergency and could facilitate on-demand production of the therapeutic at the point of care if needed. Furthermore, CFPS has potential as a production platform of biosimilars, as the patent for pembrolizumab is set to expire in 2028. Results: This work presents the design, synthesis, and target-binding affinity of a novel single-chain variable fragment of pembrolizumab (Pem-scFv) using CFPS. The CFPS production of Pem-scFv also enables the direct optimization of synthesis reaction composition and expression conditions. The conditions of 30 °C, 35% (v/v) cell extract, and an oxidizing redox environment resulted in the highest Pem-scFv soluble yield of 442 µg/mL. An affinity assay demonstrated significant binding between the CFPS-produced Pem-scFv and the PD-1 target. Computational simulations of Pem-scFv folding and binding corroborate the experimental results.

Hélesbeux J., McCarthy F.O., Silva M.M., Leitão A.J., Burke A., Salvador J.A., Moreira R., Sousa E., Moreira V.M., Marchand P.

The Group for the Promotion of Pharmaceutical Chemistry in Academia (GP2A) held its 32nd annual conference in August 2024 at the University of Coimbra, Portugal. There were 8 keynote presentations, 12 early career researcher oral presentations, and 34 poster presentations. Four awards were delivered, two for the best oral communications and two for the best poster presentations.

Morales S., Hyman P.

Rising levels of antibiotic-resistant bacteria have led to increasing interest in the use of phage therapy as an alternative treatment. While phage therapy is conceptually simple, and numerous semi-anecdotal data suggest that it could be effective if properly managed, there have been only a few randomized, double-blind clinical trials of phage therapy so far. These trials unequivocally showed that phage therapy is safe, but there is still a paucity of data on its efficacy for managing various bacterial infections. One common response to this situation is that there is a mismatch between the regulations that govern the testing of new drugs, that is, chemical agents, and biological agents like bacteriophages. Another response has been to sidestep clinical trial testing and to use phages to treat infected patients on an individual basis, sometimes called the magistral phage approach. In this paper, we argue that regulations are not the true barrier to approval of phage therapy as drugs but rather it is the lack of efficacy data. There is no one reason behind the failures of recent clinical trials. Instead, these demonstrate the complexity of implementing a therapy where both the treatment and disease are living entities interacting within another living entity, the patient. Phage banks can have an impact by monitoring these complexities during phage therapy. Importantly, phage therapy clinical trials are continuing under existing regulatory frameworks and with products manufactured under GMP (Good Manufacturing Practices).

Baturina O., Naumova N., Tupikin A., Dmitrienko E., Silnikov V., Kabilov M.

Backgound/Objective: Novel compounds for mitigating globally growing microbial resistance to antibiotics have been recently more actively researched. Triviron is a polycationic amphiphile synthetic compound with a ribonuclease activity and is used as an antiviral in veterinary medicine. Methods: We studied the effect of triviron on the mouse (line Balb/c) fecal bacteriobiome at different time points (0, 5, 25, and 120 h after a single intragastrical administration) by using amplicon sequence diversity of the V3/V4 region of 16S rRNA genes. Results: Most of the operational taxonomic units (OTUs) belonged to Bacillota (1168 OTUs, i.e., 56% of the total number of OTUs in the study) and Bacteroidota (354, i.e., 17%), with the phyla together accounting for more than 90% of the total number of sequence reads. We found changed relative abundance of some bacterial taxa with time, including the dominating Bacteroidota and Bacillota phyla; some of the changes were sex-related, although at the start of the experiment, there were no difference between the sexes in their fecal bacteriobiome composition and structure. Conclusions: The results unequivocally demonstrated that in mice, feces bacterial community structure was affected by a one-time triviron administration, even at the highest hierarchical level of phyla. The finding that the core dominant phyla can be affected, with the effect lasting at least for five days, implies that some major and important functions of the gut microbiota can be affected as well.

González-García K., Santos-Álvarez J.C., Velázquez-Enríquez J.M., Zertuche-Martínez C., Reyes-Jiménez E., Baltiérrez-Hoyos R., Vásquez-Garzón V.R.

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, disabling disorder of unknown etiology, poor prognosis, and limited therapeutic options. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA) was shown to exert resolving effects in IPF, offering a promising alternative for treating this disease; however, the molecular mechanisms associated with this effect have not been explored. Objetive: We evaluated the potential antifibrotic mechanisms of 3′5-DMBA by network pharmacology (NP) and molecular docking (MD). Methods: 3′5-DMBA-associated targets were identified by screening in SwissTargetPrediction. IPF-associated targets were identified using lung tissue meta-analysis and public databases. Common targets were identified, and a protein–protein interaction (PPI) network was constructed; we ranked the proteins in the PPI network by topological analysis. MD validated the binding of 3′5-DMBA to the main therapeutic targets. Results: A total of 57 common targets were identified between 3′5-DMBA and IPF; caspase 8, 9, 3, and 7; myeloid leukemia-induced cell differentiation protein Mcl-1; and poly [ADP-ribose] polymerase 1 are primary targets regulating PPI networks. Functional analysis revealed that the common targets are involved in the pathological features of tissue fibrosis and primarily in the apoptotic process. MD revealed favorable interaction energies among the three main targets regulating PPI networks. Conclusions: NP results suggest that the antifibrotic effect of 3′5-DMBA is due to its regulation of the pathological features of IPF, mainly by modulating signaling pathways leading to apoptosis, suggesting its therapeutic potential to treat this disease.

Sathvika V.P., Subhas P.G., Bhattacharjee D., Koppad V.N., Samrat U., Karibasappa S.B., Sagar K.M.

Background: The recurring actions and intrusive thoughts that characterise obsessive–compulsive disorder (OCD), a long-term mental illness, are known as compulsions. The cornerstones of conventional treatment are psychological counselling and prescribed medication; nonetheless, interest in complementary therapies has grown. This review looks at how well Ashwagandha, curcumin, milk thistle, valerian root, and St. John’s wort may help with OCD symptoms. Methods: To assess these herbal supplements’ potential for therapeutic benefit, case reports and clinical trials were examined. Results: Curcumin, which contains anti-inflammatory and neuroprotective properties, has shown promise in reducing the severity of OCD symptoms. Traditionally used to treat depression, St. John’s wort has shown some potential in lowering anxiety and compulsive behaviour. The herb milk thistle, which is mainly used for liver protection, did not affect OCD symptoms. Anxiolytic valerian root barely offered relief from symptoms associated with anxiety; it has only little effect on obsessions and compulsions. The adaptive Ashwagandha has demonstrated a great deal of promise in lowering stress and enhancing general well-being, which may help with symptom alleviation. Although the initial results are favourable, larger scale randomised controlled trials are necessary to validate reliability and efficacy. Conclusion: This study illustrates how herbal supplements may be used in addition to conventional medications as adjunctive treatments for OCD.

Alamelu S., Venkatesan K.B., Shagirtha K., Srinivasan M.K., Panneerselvam C., Aziz A.T., Ali Alshehri M., Seyed M.A., Pachaiappan P.

Breast cancer (BC) is the most prevalent form of malignancy among women on a global scale, ranking alongside lung cancer. Presently, conventional approaches to cancer treatment include surgical procedures followed by chemotherapy or radiotherapy. Nonetheless, the efficacy of these treatments in battling BC is often compromised due to the adverse effects they inflict on healthy tissues and organs. In recent times, a range of nanoparticles (NPs) has emerged, exhibiting the potential to specifically target malignant cells while sparing normal cells and organs from harm. This has paved the way for the development of nanoparticle-mediated targeted drug delivery systems, holding great promise as a technique for addressing BC. To increase the efficacy of this new method, several nanocarriers including inorganic NPs (such as magnetic NPs, silica NPs, etc.) and organic NPs (e.g., dendrimers, liposomes, micelles, and polymeric NPs) have been used. Herein, we discuss the mechanism of NP-targeted drug delivery and the recent advancement of therapeutic strategies of organic and inorganic nanocarriers for anticancer drug delivery in BC. We also discuss the future prospects and challenges of nanoparticle-based therapies for BC.

Perfeito M.L., Ribeiro F.D., Jesus J.R., Véras L.M., Nobre A.R., Lopes E.M., Queiroz J.C., Vasconcelos A.G., Cardoso M.G., Gonçalves J., Almeida F.R., Arcanjo D.D., Leite J.R.

This work is based on research aiming to extract and identify flavonoids from jaborandi (Pilocarpus microphyllus) leaves and investigate their antioxidant and acute antinociceptive capacity. Characterization of the constituents of the ethyl acetate fraction (EtOAcF) obtained from the methanolic extract (ME) was performed by UV-Vis spectrophotometry, infrared spectroscopy, high-performance liquid chromatography (HPLC), mass spectrometry (MS), and cyclic voltammetry, demonstrating the possible majority component of this fraction, the flavone chrysin. Its solubility properties in HPLC are very close to those of the flavonol quercetin, revealing the characteristic presence of this group. An MS spectrum of the fraction revealed a major protonated molecule of m/z 254.9 [M+H]+. The EtOAcF fraction showed three oxidation processes at 0.32 V, 0.54 V, and 0.73 V vs. Ag/AgCl. Three reduction processes at the respective potentials: 0.60 V, −0.03 V, and -0.24 V vs. Ag/AgCl, indicating potential antioxidant activity. At DPPH and ABTS antioxidant radical capture assay, The IC50 obtained was 0.5 mg/mL and 0.81 mg/mL, respectively. In vivo test to determine the mechanical nociceptive threshold in the von Frey test, the dose of 100 mg/kg of the EtOAcF was able to cause inhibition of behavioral changes in neuropathy. The results obtained in this study demonstrate the biological potential of an EtOAcF derived from jaborandi leaves.

Bahrulolum H., Beyranvand P., Ahmadian G.

Respiratory viruses present significant global health challenges due to their rapid evolution, efficient transmission, and zoonotic potential. These viruses primarily spread through aerosols and droplets, infecting respiratory epithelial cells and causing diseases of varying severity. While traditional intramuscular vaccines are effective in reducing severe illness and mortality, they often fail to induce sufficient mucosal immunity, thereby limiting their capacity to prevent viral transmission. Mucosal vaccines, which specifically target the respiratory tract’s mucosal surfaces, enhance the production of secretory IgA (sIgA) antibodies, neutralize pathogens, and promote the activation of tissue-resident memory B cells (BrMs) and local T cell responses, leading to more effective pathogen clearance and reduced disease severity. Bacillus subtilis spore surface display (BSSD) technology is emerging as a promising platform for the development of mucosal vaccines. By harnessing the stability and robustness of Bacillus subtilis spores to present antigens on their surface, BSSD technology offers several advantages, including enhanced stability, cost-effectiveness, and the ability to induce strong local immune responses. Furthermore, the application of BSSD technology in drug delivery systems opens new avenues for improving patient compliance and therapeutic efficacy in treating respiratory infections by directly targeting mucosal sites. This review examines the potential of BSSD technology in advancing mucosal vaccine development and explores its applications as a versatile drug delivery platform for combating respiratory viral infections.

Demesa-Castañeda A.V., Pérez D.J., Millán-Pacheco C., Hernández-Mendoza A., Razo-Hernández R.S.

Background: Staphylococcus aureus is a pathogen that has become resistant to different antibiotics, which makes it a threat to human health. Although the first penicillin-resistant strain appeared in 1945, nowadays, there are just a few alternatives to fight it. To circumvent this issue, novel approaches to develop drugs to target proteins of the bacteria cytoskeleton, essential for bacteria’s binary fission, are being developed. FtsZ and FtsA are two proteins that are key for the initial stages of binary fission. On one side, FtsZ forms a polymeric circular structure called the Z ring; meanwhile, FtsA binds to the cell membrane and then anchors to the Z ring. According to the literature, this interaction occurs within the C-terminus domain of FtsZ, which is mainly disordered. Objective: In this work, we studied the binding of FtsZ to FtsA using computational chemistry tools to identify the interactions between the two proteins to further use this information for the search of potential protein-protein binding inhibitors (PPBIs). Methods: We made a bioinformatic analysis to obtain a representative sequence of FtsZ and FtsA of Staphylococcus aureus. With this information, we built homology models of the FtsZ to carry out the molecular docking with the FtsA. Furthermore, alanine scanning was conducted to identify the key residues forming the FtsZ–FtsA complex. Finally, we used this information to generate a pharmacophore model to carry out a virtual screening approach. Results: We identified the key residues forming the FtsZ-FtsA complex as well as five molecules with high potential as PPBIs.

Chávez-Hernández A.L., Rodríguez-Pérez J.R., Cortés-Hernández H.F., Valencia-Sanchez H.A., Chávez-Fumagalli M.Á., Medina-Franco J.L.

Fragment libraries have a major significance in drug discovery due to their role in de novo design and enumerating large and ultra-large compound libraries. Although several fragment libraries are commercially available, most are derived from synthetic compounds. The number of fragment libraries derived from natural products is still being determined. Still, they represent a rich source of building blocks to generate pseudo-natural products and bioactive synthetic compounds inspired by natural products. In this work, we generated and analyzed a fragment library of natural products from Colombia, a highly diverse geographical region where fragment libraries are yet to be reported. We also generated and reported fragment libraries of three novel natural product libraries and, as a reference, the most updated version of FDA-approved drugs. In line with the principles of open science, the fragment libraries developed in this study are freely available.